BTIG lowered the firm’s price target on DexCom (DXCM) to $107 from $120 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in the MedTech space. The sector had been seen as a safe haven, but quarterly results will matter less than a company’s ability to navigate ahead, the analyst tells investors in a research note. Between a frenetic trade war largely now directed at China to cuts at many federal healthcare agencies, investors will want answers which companies may not be able to provide, and this may weigh on sentiment, the firm adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Dexcom’s G7 Sensor Approval Boosts Buy Rating Amid Strategic Advancements
- Dexcom’s Promising Outlook: FDA Approval and Market Expansion Drive Buy Rating
- Dexcom’s Strategic Advances and FDA Clearance Propel Buy Rating
- Dexcom’s G7 Sensor Approval and Strategic Moves Drive Buy Rating
- Prada to acquire Versace, CarMax reports mixed Q4 results: Morning Buzz
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue